IM Boards Flashcards
(358 cards)
Preferred modality to work up possible CAD in patients with LBBB
In patients with left bundle branch block undergoing myocardial perfusion imaging, **vasodilator-induced stress **is preferred to exercise or dobutamine because of the potential for false-positive septal perfusion abnormalities.
Vasodilators:
-dipyridamole
-regadenoson
-adenosine
Concerns with ranolazine
-QT prolongation
-P-450 3A4 (CYP3A4)
dose reduction is indicated in patients receiving moderate inhibitors of cytochrome P-450 3A4 (CYP3A4), such as verapamil and diltiazem. Ranolazine should not be used in combination with strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, several HIV medications) because of resultant increases in ranolazine serum levels.
Who might benefit from extended (>12 months) DAPT after STEMI/NSTEMI?
-diabetes
-depressed LVF
-saphenous vein graft stenting
Duration of DAPT after DES for chronic stable angina
6 months (but less i.e. 3 months if high bleeding risk)
Anti-arrhythmic classes
Drug classes:
IB: sodium channel blockade (lodicaine, mexiletine)
IC: sodium channel blockade (flecanide, propafenone)
II: beta blockers (metoprolol, propranolol, carvedilol, atenolol, bisoprolol, nadolol)
III: potassium channel blockade (sotalol, dofetilide)
IV: nondihydropyridine calcium channel blockers (verapamil, diltiazem)
Multichannel blockers: amiodarone, dronedarone
Adenosine receptor agonists: adenosine
Cardiac glycoside: digoxin
Note:
-classes I and III are most effective as antiarrhythmics, but also the most pro-arrthymic
Class IC anti-arrhythmics
Flecainide and propafenone are the most commonly used class I agents (IC); they are primarily used to treat atrial arrhythmias and usually in conjunction with AV nodal blockers to prevent 1:1 atrial flutter.
Toxicity can manifest as QRS widening.
Class IC agents are contraindicated in patients with ischemic or structural heart disease because of the risk for promoting ventricular arrhythmias and death.
Class III anti-arrhythmics
Class III agents sotalol and dofetilide are used to treat atrial and ventricular arrhythmias.
Class III antiarrhythmic therapy typically is initiated in an inpatient setting, with regular assessment of the corrected QT interval (QTc) and caution exercised in patients with kidney disease.
Dofetilide is particularly notorious for common and dangerous drug-drug interactions.
Amiodarone, a class III multichannel blocker, is frequently used to treat patients with recurrent ventricular tachycardia (VT) or AF. Amiodarone has a low risk of pro-arrhythmia; however, it is associated with thyroid, liver, lung, and eye toxicities as well as neurologic side effects. Thyroid and liver function should be monitored every 6 months, and pulmonary function testing and ophthalmologic examination should be performed annually. Amiodarone interacts with many drugs, including warfarin, statins, and digoxin. Dronedarone, another class III multichannel blocker, can be used in patients with paroxysmal AF and no overt heart failure.
Amiodarone toxicity
Amiodarone, a class III multichannel blocker, is frequently used to treat patients with recurrent ventricular tachycardia (VT) or AF.
Amiodarone has a low risk of pro-arrhythmia; however, it is associated with thyroid, liver, lung, and eye toxicities as well as neurologic side effects. Thyroid and liver function should be monitored every 6 months, and pulmonary function testing and ophthalmologic examination should be performed annually.
Amiodarone interacts with many drugs, including warfarin, statins, and digoxin.
Dronedarone, another class III multichannel blocker, can be used in patients with paroxysmal AF and no overt heart failure.
Postural orthostatic tachycardia syndrome (POTS)
Postural orthostatic tachycardia syndrome (POTS) is another condition that often presents with tachycardia. POTS is a form of dysautonomia characterized by orthostatic intolerance and excessive tachycardia, particularly with standing.
Diagnostic criteria for POTS include an increase in heart rate of 30/min or more or an increase to greater than 120/min within 10 minutes of standing. The diagnosis is often confirmed with tilt-table testing.
Behavioral modification, compression stockings, exercise training, and increased fluid intake are important components of therapy. Medical therapy for POTS is highly variable and may include β-blockers, ivabradine (off-label use), fludrocortisone, selective serotonin reuptake inhibitors (off-label use), midodrine, and pyridostigmine (off-label use).
Atrioventricular Nodal Reentrant Tachycardia
AVNRT accounts for two thirds of all cases of SVT, not including cases of AF and atrial flutter. It is caused by a reentrant circuit within the AV node that uses both the fast and slow pathways. AVNRT is characterized by a short RP interval with a retrograde P wave inscribed very close to the QRS complex.
(best seen in lead V1, appearing as a pseudo r′ wave.)
AVNRT may be terminated with vagal maneuvers or adenosine. AV nodal blockers (β-blockers or calcium channel blockers) are used to prevent recurrent AVNRT. In patients with recurrent AVNRT and those who do not tolerate or prefer to avoid long-term medical therapy, catheter ablation should be considered. Catheter ablation of AVNRT has a high success rate, although it is associated with a 1% risk for injury to the AV node necessitating pacemaker implantation.
Atrioventricular Reciprocating Tachycardia
AVRT is an accessory pathway–mediated tachycardia that is often observed as preexcitation (delta wave) on ECG. Early ventricular activation over the accessory pathway causes shortening of the PR interval, and the initial part of the QRS complex is slurred because of premature ventricular depolarization in the myocardial tissue adjacent to the accessory pathway.
In AVRT, **conduction is anterograde over the AV node (orthodromic, narrow-complex AVRT) in 90% to 95% of cases; conduction is anterograde over the accessory pathway (antidromic, wide-complex AVRT) in the remaining cases.
**
Wolff-Parkinson-White (WPW) syndrome is defined by symptomatic AVRT with evidence of preexcitation on resting ECG. AF occurs in up to one-third of patients with WPW syndrome. Rapid conduction over an accessory pathway in AF can result in ventricular fibrillation (VF) and sudden cardiac death (SCD), although this occurs in less than 1% of cases of WPW syndrome.
Risk stratification for SCD can be performed with exercise testing, although more frequently, patients are referred for electrophysiology testing for both risk stratification and curative ablation. Catheter ablation is first-line therapy for patients with WPW syndrome. The success rate for ablation is high but is dictated by the location of the accessory pathway. Antiarrhythmic therapy is second-line therapy.
In asymptomatic patients with preexcitation on ECG, management is controversial. Invasive testing is generally not required unless the patient has a high-risk occupation, such as a commercial airline pilot.
Who needs anticoagulation in atrial fibrillation?
The 2019 American College of Cardiology/American Heart Association/Heart Rhythm Society focused update on AF recommends anticoagulation to prevent stroke in patients with nonvalvular AF who have a CHA2DS2-VASc score of 2 or greater in men or 3 or greater in women.
American College of Chest Physicians: one or more non-sex CHA2DS2-VASc stroke risk factors (score of ≥1 in men or ≥2 in women).
Anticoagulation options for atrial fibrillation
-warfarin (vitK antagonist)
-dabigitran (direct thrombin inhibitor)
-Xa inhibitors: rivaroxaban, apixaban, edoxaban
Only warfarin should be used for valvular AF (moderate/severe mitral stenosis or mechanical valve prosthesis)
Dabigitran is SUPERIOR to warfarin (and has less intracranial bleeding), but has higher risk of GI bleeding and dyspepsia
Apixaban is SUPERIOR to warfarin and has less bleeding risk everywhere.
Rivaroxaban and edoxaban are noninferior to warfarin, but have less major bleeding.
Of the Xa inhibitors, apixaban is bid (and has lower bleeding risk)
DOAC reversal
**Andexanet alfa or 4-factor prothrombin complex concentrates **are recommended for life-threatening bleeding due to rivaroxaban, apixaban, or edoxaban.
Idarucizumab is a dabigatran-reversal agent available for emergency invasive or surgical procedures or in cases of uncontrolled or life-threatening bleeding.
Management of patient with stable coronary artery disease and atrial fibrillation
Rivaroxaban
In patients with AF and stable CAD, treatment with rivaroxaban alone is noninferior to rivaroxaban plus aspirin in the prevention of the composite end point of stroke, systemic embolization, myocardial infarction (MI), need for revascularization, or death from any cause. Rivaroxaban monotherapy also is associated with significantly less bleeding.
Management of atrial fibrillation in HFrEF
In patients with heart failure with reduced ejection fraction, recent clinical trials have shown that catheter ablation of AF is associated with a favorable effect on morbidity and mortality compared with medical therapy.
Management of atrial fibrillation in HFrEF
In patients with heart failure with reduced ejection fraction, recent clinical trials have shown that catheter ablation of AF is associated with a favorable effect on morbidity and mortality compared with medical therapy.
Management of atrial flutter
Management of anticoagulation in the setting of chronic atrial flutter is similar to that for AF; however, a rhythm control strategy is favored in atrial flutter because rate control may be difficult and often requires high doses of more than one AV nodal blocker. Catheter ablation is the definitive treatment for typical atrial flutter because of a very high success rate (>95%) and low complication rate. Oral anticoagulation in patients with atrial flutter without ablation is approached in the same manner as in patients with AF.
Differential diagnosis of wide complex tachycardia
The differential diagnosis for wide-complex tachycardia include “
-SVT with aberrancy
-preexcited tachycardia (antidromic AVRT)
-ventricular paced rhythms
-VT (most common)
Key features of VT on EKG
Key features of VT on ECG include
-AV dissociation
-fusion beats
-capture beats
Several important clinical and ECG features can distinguish VT from other conditions. The presence of irregular jugular venous pulsations of greater amplitude than normal venous waves (cannon waves) signal the presence of atrioventricular dissociation and support the diagnosis of VT. Wide-complex tachycardias that are positive in lead aVR, have a QRS morphology that is concordant (all predominantly positive or negative) in the precordial leads, have QRS morphology other than typical right or left bundle branch block, and exhibit extreme axis deviation (“northwest” axis) are usually VT. Fusion beats (supraventricular and ventricular impulses coinciding to produce a hybrid complex) (arrows in the ECG shown below) and capture beats (a sinus conducted beat producing a normal QRS) are all highly suggestive of VT. Of importance, the fact that the patient is awake, alert, and interactive and/or has a measurable blood pressure does not exclude VT.
Management of ventricular tachycardia
Hemodynamic instability:
-immediate direct current cardioversion
-IV amiodarone if VT persists or recurs after cardioversion.
-if ST-elevation MI –> emergency revascularization
Hemodynamically stable (and not in the setting of an acute MI)
-IV procainamide
-IV amiodarone or sotalol may also be considered.
In patients with idiopathic VT, calcium channel blockers, especially verapamil, and β-blockers are first-line therapy. (Catheter ablation if medical options fail)
Indications for ICD
Patients with sustained ventricular arrhythmias (>30 seconds) or cardiac arrest without a reversible cause have a class 1 recommendation for secondary-prevention ICD placement.
ICD placement is recommended for the primary prevention of SCD in patients with ischemic or nonischemic cardiomyopathy, ejection fraction less than 35%, and New York Heart Association functional class II or III heart failure.
Permanent pacemaker indications
-symptomatic bradycardia without reversible cause
-permanent atrial fibrillation with symptomatic bradycardia
-alternating bundle branch block
-complete heart block, high-degree atrioventricular (AV) block, or Mobitz type 2 second-degree AV block, irrespective of symptoms
EAST-AFNET 4
In patients with recently diagnosed atrial fibrillation and concomitant cardiovascular conditions, **early rhythm control **(antiarrhythmic drugs or ablation) reduces the primary composite end point of cardiovascular death, stroke, or hospitalization for heart failure or acute coronary syndrome compared with usual care.